A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Gastroenterology

• Publication date

  1999-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0016-5085(99)70334-3PMID 10500058
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Endoscopic evaluation of etodolac and naproxen, and their relative effects on gastric and duodenal prostaglandins

  2005cited by this paper
• Specific inhibition of cyclooxygenase‐2 with MK‐0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen

  1999cited by this paper
• Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.

  1999cited by this paper
• Comparison of the upper gastrointestinal safety of Arthrotec 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers.

  1999cited by this paper
• Characterization of rofecoxib as a cyclooxygenase‐2 isoform inhibitor and demonstration of analgesia in the dental pain model

  1999cited by this paper
• Localization of cyclooxygenase-2 and regulation of its expression in gastric ulcers in rats

  1998cited by this paper
• NSAID induced gastrointestinal complications: the ARAMIS perspective--1997. Arthritis, Rheumatism, and Aging Medical Information System.

  1998cited by this paper
• Has the impact of helicobacter pylori therapy on ulcer recurrence in the united states been overstated?

  1998cited by this paper
• Role of cyclooxygenase-2 in the healing of gastric ulcers in rats.

  1998cited by this paper
• Adverse effects of nonsteroidal anti-inflammatory drugs on the gastrointestinal system.

  1998cited by this paper
• High-dose famotidine for prevention of NSAID ulcers?

  1997cited by this paper
• Nonsteroidal anti-inflammatory drug gastropathy.

  1996cited by this paper
• Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis

  1996cited by this paper
• A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors

  1996cited by this paper
• Helicobacter pylori and complicated ulcer disease.

  1996cited by this paper
• Misoprostol Reduces Serious Gastrointestinal Complications in Patients with Rheumatoid Arthritis Receiving Nonsteroidal Anti-Inflammatory Drugs

  1995cited by this paper
• A randomized double-blind comparison of placebo, etodolac, and naproxen on gastrointestinal injury and prostaglandin production.

  1995cited by this paper
• Misoprostol coadministered with diclofenac for prevention of gastroduodenal ulcers

  1995cited by this paper
• A controlled study of ranitidine for the prevention of recurrent hemorrhage from duodenal ulcer

  1994cited by this paper
• Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs.

  1993cited by this paper
• Duodenal and Gastric Ulcer Prevention with Misoprostol in Arthritis Patients Taking NSAIDs

  1993cited by this paper
• A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa.

  1993cited by this paper
• Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase.

  1993cited by this paper
• A double‐blind gastroscopic evaluation of the effects of etodolac and naproxen on the gastrointestinal mucosa of rheumatic patients

  1991cited by this paper
• NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal.

  1991cited by this paper
• Host-parasite interaction in the pathogenesis of rheumatic fever.

  1991cited by this paper
• Comparison of salsalate and aspirin on mucosal injury and gastroduodenal mucosal prostaglandins.

  1990cited by this paper
• A randomized study of maintenance therapy with ranitidine to prevent the recurrence of duodenal ulcer.

  1989cited by this paper
• FDA Arthritis Advisory Committee meeting: postmarketing surveillance of nonsteroidal antiinflammatory drugs.

  1985cited by this paper

• Is ibuprofen associated with upper gastrointestinal bleeding? A systematic review and meta-analysis

  2025influential citation
• Diffusion Limit and the Reactivity/Affinity Conundrum: Implications for Optimization and Hit Finding for Irreversible Modulators.

  2025cites this paper
• The clinical and endoscopic aspects of peptic ulcers secondary to the use of nonsteroidal anti-inflammatory drugs of various origins

  2021cites this paper
• Rheumatologische Erkrankungen und der Gastrointestinaltrakt

  2021cites this paper
• Evidence-based clinical practice guidelines for peptic ulcer disease 2020

  2021cites this paper
• 약제 연관 소화성궤양의 임상 진료지침 개정안 2020

  2020cites this paper
• Structural investigation on the selective COX-2 inhibitors mediated cardiotoxicity: A review.

  2020cites this paper
• Clinical Guidelines for Drug-Related Peptic Ulcer, 2020 Revised Edition

  2020cites this paper
• Stable Discovery of Interpretable Subgroups via Calibration in Causal Studies

  2020cites this paper
• NSAID, antiaggregant, and/or anticoagulant-related upper gastrointestinal bleeding: Is there any change in prophylaxis rate after a 10-year period?

  2019cites this paper
• Safety of Cyclooxygenase-2 Inhibitors in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis

  2019cites this paper
• Novel aryl carboximidamide and 3-aryl-1,2,4-oxadiazole analogues of naproxen as dual selective COX-2/15-LOX inhibitors: Design, synthesis and docking studies.

  2019cites this paper
• Gastrointestinal risk factors and patient‐reported outcomes of ankylosing spondylitis in Korea

  2019cites this paper
• Nonsteroidal Anti-Inflammatory Drug-Gastropathy and Enteropathy

  2019cites this paper
• Medical Treatment of Joint Disease

  2019cites this paper
• Electric charge conversable drug liposomes enable to enhance treatment efficacy of breast cancer

  2019cites this paper
• Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial

  2018cites this paper
• Epiisopiloturine hydrochloride, an imidazole alkaloid isolated from Pilocarpus microphyllus leaves, protects against naproxen-induced gastrointestinal damage in rats.

  2017cites this paper
• A study on clinical profile and risk factors in drug induced UGI bleeding

  2017cites this paper
• Discovery of a COX-2 selective inhibitor hit with anti-inflammatory activity and gastric ulcer protective effect.

  2017cites this paper
• Pharmacokinetics of DFN-15, a Novel Oral Solution of Celecoxib, Versus Celecoxib 400-mg Capsules: A Randomized Crossover Study in Fasting Healthy Volunteers

  2017cites this paper
• Prevalence of upper gastrointestinal bleeding risk factors among the general population and osteoarthritis patients

  2016cites this paper
• Gastrointestinal safety and efficacy of long-term GCSB-5 use in patients with osteoarthritis: A 24-week, multicenter study.

  2016cites this paper
• Management of NSAID-associated peptic ulcer disease

  2016cites this paper
• Comparison of benefit–risk preferences of patients and physicians regarding cyclooxygenase-2 inhibitors using discrete choice experiments

  2016cites this paper
• Testing the usefulness of the number needed to treat to be harmed (NNTH) in benefit-risk evaluations: case study with medicines withdrawn from the European market due to safety reasons

  2016cites this paper
• Hepatotoxicity induced by coxibs: how concerned should we be?

  2016cites this paper
• WITHDRAWN: Botulinum toxin for subacute/chronic neck pain.

  2015cites this paper
• WITHDRAWN: Medicinal and injection therapies for mechanical neck disorders.

  2015cites this paper
• Medicinal and injection therapies for mechanical neck disorders.

  2015cites this paper
• Gastrointestinal Adverse Reactions from Ibuprofen

  2015cites this paper
• Recomendaciones para una prescripción segura de antiinflamatorios no esteroideos: documento de consenso elaborado por expertos nominados por 3 sociedades científicas (SER-SEC-AEG)☆

  2014cites this paper
• Recomendaciones para una prescripción segura de antiinflamatorios no esteroideos: documento de consenso elaborado por expertos nominados por 3 sociedades científicas (SER-SEC-AEG)

  2014cites this paper
• Safe prescription recommendations for non steroidal anti-inflammatory drugs: consensus document ellaborated by nominated experts of three scientific associations (SER-SEC-AEG).

  2014cites this paper
• Endos507 8__15

  2014cites this paper
• Safe Prescription Recommendations for Non Steroidal Anti-inflammatory Drugs: Consensus Document Elaborated by Nominated Experts of Three Scientific Associations (SER-SEC-AEG)

  2014cites this paper
• Omega-3 fatty acids: a novel resort against gastrointestinal injury.

  2014cites this paper
• [Safe prescription recommendations for non steroidal anti-inflammatory drugs: Consensus document ellaborated by nominated experts of three scientific associations (SER-SEC-AEG)].

  2014cites this paper
• Cyclooxygenase (COX)-1 and COX-2 Both Play an Important Role in the Protection of the Duodenal Mucosa in Cats

  2013cites this paper
• Endoscopic ulcers as a surrogate marker of NSAID-induced mucosal damage.

  2013cites this paper
• Postoperative Pain, COX-2 Inhibitors

  2013cites this paper
• Endoscopic ulcers as a surrogate marker of NSAID-induced mucosal damage

  2013cites this paper
• Current Perspectives in NSAID-Induced Gastropathy

  2013cites this paper
• Efficacy and tolerability of naproxen/esomeprazole magnesium tablets compared with non-specific NSAIDs and COX-2 inhibitors: a systematic review and network analyses

  2013cites this paper
• Clinical Potential of Cyclo-Oxygenase-2 Inhibitors

  2012cites this paper
• Title Page. Jpet #199182 Introduction

  2012cites this paper
• Modelling Therapeutic Strategies in the Treatment of Osteoarthritis

  2012cites this paper
• Rofecoxib

  2012cites this paper
• Chapter 79 – Medical Treatment of Joint Disease

  2012cites this paper
• Patologia Gastroduodenal Associada ao Consumo de Agentes Anti-Inflamatórios Não Esteróides, Incluindo os Inibidores da Enzima Ciclooxigenase-2 e o Ácido Acetilsalicílico

  2012cites this paper
• PHARMACOVIGILANCE FOR ADVERSE DRUG REACTIONS IN PATIENTS ON NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND HEPATIC DYSFUNCTION IN ACECLOFENAC THERAPY IN SOUTH DELHI HOSPITAL Research Article

  2012cites this paper
• Innovations in Post-Marketing Safety Research

  2012cites this paper
• A COMPARATIVE STUDY OF EFFICACY AND SAFETY OF DICLOFENAC AND ACECLOFENAC IN THE TREATMENT OF OSTEOARTHRITIS PATIENTS

  2012cites this paper
• Epidemiology and demographics of upper gastrointestinal bleeding: prevalence, incidence, and mortality.

  2011cites this paper
• Helicobacter pylori related and non-related lesions in the stomach.

  2011cites this paper
• Using clinical trial data and linked administrative health data to reduce the risk of adverse events associated with the uptake of newly released drugs by older Australians: a model process

  2011cites this paper
• Gastrointestinal and Cardiovascular Risk of Nonsteroidal Anti-inflammatory Drugs.

  2011cites this paper
• Rofecoxib and Clinically Significant Upper and Lower Gastrointestinal Events Revisited Based on Documents From Recent Litigation

  2011cites this paper
• Botulinum toxin for subacute/chronic neck pain.

  2011cites this paper
• Prevention of NSAID-induced gastroduodenal ulcers (Review)

  2011cites this paper
• Analgesics and Antipyretics, 2. Nonsteroidal Anti‐inflammatory Drugs

  2011cites this paper
• The Interaction of H. pylori and Non-Steroidal Anti-Inflammatory Drugs and Their Effect on Induction of Peptic Ulcer

  2011cites this paper
• The ulcer sleuths: The search for the cause of peptic ulcers

  2011cites this paper
• [Evaluation model of the effect of Rofecoxib on the co-prescription of gastroprotective agents observed during the treatment of osteoarthritis].

  2011cites this paper
• Rofecoxib does not appear to increase the risk of venous thromboembolism: a systematic review of the literature.

  2011cites this paper
• Nonsteroidal Anti-Inflammatory Drug-Induced Gastroduodenal Bleeding: Risk Factors and Prevention Strategies

  2010cites this paper
• Emotion recollected in tranquility: lessons learned from the COX-2 saga.

  2010cites this paper
• Current Status of Gastroduodenal Ulcers

  2010cites this paper
• Non‐Steroidal Anti‐Inflammatory Drug‐Induced Gastro‐Duodenal Toxicity

  2010cites this paper
• Can postoperative analgesia be improved by the choice and timing of analgesics? : Studies on nonsteroidal analgesics and opioids with special focus on opioid-induced hyperalgesia

  2010cites this paper
• Role of coxibs in the strategies for gastrointestinal protection in patients requiring chronic non-steroidal anti-inflammatory therapy.

  2009cites this paper
• Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillance.

  2009cites this paper
• Meta‐analysis: incidence of endoscopic gastric and duodenal ulcers in placebo arms of randomized placebo‐controlled NSAID trials

  2009cites this paper
• double blind study versus placebo and celecoxib osteoarthritis of the knee: a 13 week, randomised, Lumiracoxib is effective in the treatment of

  2009cites this paper
• Clinical study of upper gastrointestinal bleeding associated with low-dose aspirin in Japanese patients.

  2009cites this paper
• Digest Itself? Prostaglandins, NSAIDs, and Gastric Mucosal Protection: Why Doesn't the Stomach

  2009cites this paper
• Pattern of use and safety of non-steroidal anti-inflammatory drugs in rheumatoid arthritis patients. A prospective analysis from clinical practice.

  2009cites this paper
• Guidelines for Prevention of NSAID-Related Ulcer Complications

  2009cites this paper
• Cardiovascular risks of COX inhibition: current perspectives.

  2008cites this paper
• Ulcers and gastritis

  2008cites this paper
• Systematic review: ulcer definition in NSAID ulcer prevention trials

  2008cites this paper
• Roles of NSAIDs and aspirin in bleeding peptic ulcers

  2008cites this paper
• COX-2 selective inhibitors in the treatment of osteoarthritis.

  2008cites this paper
• Gastric mucosal defense and cytoprotection: bench to bedside.

  2008cites this paper
• MF63 [2-(6-Chloro-1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a Selective Microsomal Prostaglandin E Synthase-1 Inhibitor, Relieves Pyresis and Pain in Preclinical Models of Inflammation

  2008cites this paper
• Recommendations for use of selective and nonselective nonsteroidal antiinflammatory drugs: an American College of Rheumatology white paper.

  2008cites this paper
• Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.

  2008cites this paper
• Efficacy and tolerability of lumiracoxib, a highly selective cyclo-oxygenase-2 (COX2) inhibitor, in the management of pain and osteoarthritis

  2008cites this paper
• UTILISATION DES ANTI-INFLAMMATOIRES NON STEROÏDIENS EN CHIMIOTHERAPIE ANTI-CANCEREUSE : ACTUALITES

  2008cites this paper
• Cardiovascular risks of COX inhibition: current perspectives

  2008cites this paper
• Gastrointestinal and cardiovascular risks of nonsteroidal anti-inflammatory drugs.

  2008cites this paper
• Acute NSAID-related transmural duodenitis and extensive duodenal ulceration.

  2007cites this paper
• Hospitalization for gastrointestinal adverse events attributable to the use of low‐dose aspirin among patients 50 years or older also using non‐steroidal anti‐inflammatory drugs: a retrospective cohort study

  2007cites this paper
• Cardiovascular effects of the selective cyclooxygenase-2 inhibitors.

  2007cites this paper
• Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial.

  2007cites this paper
• The effect of low-dose aspirin on the decreased risk of development of dyspepsia and gastrointestinal ulcers associated to cyclooxygenase-2 selective inhibitors.

  2007cites this paper
• Eradication of Helicobacter pylori Does Not Reduce the Incidence of Gastroduodenal Ulcers in Patients on Long‐term NSAID Treatment: Double‐Blind, Randomized, Placebo‐Controlled Trial

  2007cites this paper
• Effect of meloxicam on postoperative pain relief after inguinal hernia repair with local anaesthesia.

  2007cites this paper
• Prospective, Double-Blinded, Randomized, Placebo-Controlled Comparison of Local Anesthetic and Nonsteroidal Anti-Inflammatory Drugs for Postoperative Pain Management after Laparoscopic Surgery

  2007cites this paper
• Risk of myocardial infarction associated with selective COX‐2 inhibitors: Meta‐analysis of randomised controlled trials

  2007cites this paper